HONG KONG – The CFDA approved the country's first-ever orally administrated and subtype-selective histone deacetylase inhibitor (HDACi). Patients in China with relapsed or refractory peripheral T-cell lymphoma (PTCL) now have an alternative treatment other than traditional chemotherapy.